ResearcherHospital Italiano de Buenos AiresNo recent work listed

Ignacio Guillermo Merlo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5913-1836; OpenAlex author ID A5030184202. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper

Papers 2

Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker? Co-author DOI 10.1007/s12029-022-00839-7 ↗
[Long-term survival after pancreatic cancer surgery]. Co-author PMID 34633955 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Oscar Mazza · 2 shared papers, 2021–2023 · strength 0.33
- Paper Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker? DOI 10.1007/s12029-022-00839-7 ↗
- Paper [Long-term survival after pancreatic cancer surgery]. PMID 34633955 ↗
Martín de Santibañes · 2 shared papers, 2021–2023 · strength 0.33
- Paper Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker? DOI 10.1007/s12029-022-00839-7 ↗
- Paper [Long-term survival after pancreatic cancer surgery]. PMID 34633955 ↗
Eduardo de Santibáñes · 2 shared papers, 2021–2023 · strength 0.33
- Paper Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker? DOI 10.1007/s12029-022-00839-7 ↗
- Paper [Long-term survival after pancreatic cancer surgery]. PMID 34633955 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.